Skip to main content

Table 2 Univariate and multivariable analyses of Disease Free Survival (DFS) and Overall Survival (OS) for the different immune markers and for tumor immune phenotypes

From: Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study

DFS OS
Univariate analysis Multivariable analysis** Univariate analysis Multivariable analysis**
  HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
HLA class I    0.013*    0.548    0.075    0.984
Loss 1.00    1.00    1.00    1.00  
Downregulation 0.84 0.58-1.22   1.08 0.72-1.62   0.78 0.53-1.15   1.04 0.68-1.59
Expression 0.64 0.46-0.89   0.91 0.63-1.32   0.68 0.49-0.95   1.03 0.70-1.52
Foxp3+    <0.001*    0.012*    <0.001*    0.018*
Below median 1.00    1.00    1.00    1.00  
Above median 0.62 0.49-0.79   0.72 0.56-0.93   0.64 0.50-0.81   0.73 0.56-0.95
HLA-G    0.042*    0.849    0.056    0.418
Weak expression 1.00    1.00    1.00    1.00  
Strong expression 0.75 0.57-0.99   0.85 0.63-1.13   0.76 0.58-1.01   0.88 0.66-1.19
Immune phenotype    <0.001*    0.019*    <0.001*    0.122
Phenotype 1 1.00    1.00    1.00    1.00  
Phenotype 2 1.26 0.94-1.68   1.13 0.83-1.54   1.18 0.87-1.58   1.07 0.78-1.47
Phenotype 3 2.06 1.54-2.75   1.56 1.14-2.14   1.88 1.40-2.53   1.39 1.01-1.92
TNM stage    <0.001*       <0.001*    
I-II 1.00       1.00     
III-IV 2.65 2.09-3.37      2.65 2.08-3.38    
Circumferential margin    <0.001*       <0.001*    
Negative 1.00       1.00     
Positive 2.26 1.73-2.94      2.42 1.85-3.16    
Age (continuous) 1.03 1.02-1.04 <0.001*     1.04 1.03-1.05 <0.001*    
Tumor grade    0.094       0.058    
Well 1.00       1.00     
Moderate 0.88 0.53-1.46      0.87 0.52-1.44    
Poor 1.19 0.69-2.04      1.21 0.70-2.09    
Adjuvant chemotherapy    <0.001*       <0.001*    
No 1.00       1.00     
Yes 2.38 1.77-3.20      2.43 1.80-3.28    
  1. *Statistical significance.
  2. **Corrected for TNM stage, circumferential margin, age, tumor grade and adjuvant therapy.